Covered recipient · General Payments record
AARON MILSTONE
Allopathic & Osteopathic Physicians Internal Medicine Pulmonary Disease
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2020 · Entire year
$116,376.14
146 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2020 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $95,297.75 | 60 |
| Consulting Fee | $11,238.00 | 5 |
| Travel and Lodging | $7,251.09 | 27 |
| Food and Beverage | $2,584.26 | 53 |
| Education | $5.04 | 1 |
By paying entity
PY2020 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Mylan Specialty L.P. | $34,348.09 | 36 |
| GlaxoSmithKline, LLC. | $29,024.46 | 30 |
| Genentech USA, Inc. | $27,149.65 | 24 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $14,675.75 | 16 |
| Insmed, Inc. | $10,452.16 | 22 |
| AstraZeneca Pharmaceuticals LP | $404.86 | 5 |
| United Therapeutics Corporation | $112.70 | 2 |
| Actelion Pharmaceuticals US, Inc. | $55.51 | 2 |
| Novartis Pharmaceuticals Corporation | $31.39 | 2 |
| Philips Electronics North America Corporation | $22.75 | 1 |
| Arbor Pharmaceuticals, Inc. | $21.31 | 1 |
| Grifols USA, LLC | $20.50 | 1 |
| Merck Sharp & Dohme Corporation | $16.40 | 1 |
| Resmed Corp | $14.79 | 1 |
| Pulmonx Corporation | $14.00 | 1 |
| Sunovion Pharmaceuticals Inc. | $11.82 | 1 |
Page 2 of 3; records 51–100 of 146 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
AARON MILSTONE
NPI 1134211550 · CMS profile ID 232262
Allopathic & Osteopathic Physicians / Internal Medicine / Pulmonary Disease
FRANKLIN, TN
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 3; records 51–100 of 146 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1134211550?year=2020&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- AARON MILSTONE, NPI 1134211550, CMS profile ID 232262. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 146 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1134211550?year=2020&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
- APA 7
- IndustryPayments. (2026). AARON MILSTONE, NPI 1134211550, CMS profile ID 232262. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 146 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1134211550?year=2020&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
- Bluebook
- AARON MILSTONE, NPI 1134211550, CMS profile ID 232262, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 146 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1134211550?year=2020&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2020
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30
146 matching records · $116,376.14 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–100 of 146.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | $18.65 | 08/13/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 738533911 | CMS |
| Mylan Specialty L.P. | $1,064.00 | 08/12/2020 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 751385617 | CMS |
| Mylan Specialty L.P. | $74.25 | 08/01/2020 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 751388377 | CMS |
| AstraZeneca Pharmaceuticals LP | $31.90 | 07/13/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 736086163 | CMS |
| Insmed, Inc. | $5.04 | 07/07/2020 | Education | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 739693899 | CMS |
| GlaxoSmithKline, LLC. | $1,200.00 | 06/30/2020 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 738578087 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $25.76 | 06/17/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 720491263 | CMS |
| GlaxoSmithKline, LLC. | $1,200.00 | 06/16/2020 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 738627777 | CMS |
| GlaxoSmithKline, LLC. | $14.17 | 06/02/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 738798669 | CMS |
| Mylan Specialty L.P. | $750.00 | 06/01/2020 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 751388361 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $22.24 | 05/21/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 720491267 | CMS |
| Grifols USA, LLC | $20.50 | 05/21/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 750411031 | CMS |
| GlaxoSmithKline, LLC. | $1,200.00 | 05/19/2020 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 738534637 | CMS |
| Insmed, Inc. | $20.95 | 05/19/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 739693983 | CMS |
| Mylan Specialty L.P. | $349.05 | 05/17/2020 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 751408259 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $17.90 | 05/12/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 720491271 | CMS |
| Sunovion Pharmaceuticals Inc. | $11.82 | 05/11/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 748397143 | CMS |
| United Therapeutics Corporation | $12.70 | 05/07/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 752463547 | CMS |
| GlaxoSmithKline, LLC. | $19.79 | 05/05/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 738936905 | CMS |
| Actelion Pharmaceuticals US, Inc. | $33.42 | 04/27/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 718926569 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $4,008.00 | 04/24/2020 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 720985649 | CMS |
| Insmed, Inc. | $25.93 | 04/23/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 739690321 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $2,025.00 | 04/09/2020 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 720491295 | CMS |
| GlaxoSmithKline, LLC. | $1,200.00 | 04/07/2020 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 738588781 | CMS |
| Mylan Specialty L.P. | $2,025.00 | 04/01/2020 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 751390501 | CMS |
| GlaxoSmithKline, LLC. | $16.44 | 03/27/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 738795801 | CMS |
| Mylan Specialty L.P. | $795.00 | 03/26/2020 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 751383749 | CMS |
| Mylan Specialty L.P. | $795.00 | 03/26/2020 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 751383913 | CMS |
| Genentech USA, Inc. | $3,720.00 | 03/05/2020 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 742971495 | CMS |
| Genentech USA, Inc. | $124.64 | 03/05/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 742971503 | CMS |
| Genentech USA, Inc. | $555.06 | 03/05/2020 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 742971508 | CMS |
| GlaxoSmithKline, LLC. | $1,200.00 | 03/05/2020 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 738535389 | CMS |
| Resmed Corp | $14.79 | 03/02/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 751836293 | CMS |
| Mylan Specialty L.P. | $2,025.00 | 03/01/2020 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 751385145 | CMS |
| GlaxoSmithKline, LLC. | $900.00 | 02/24/2020 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 738732785 | CMS |
| Pulmonx Corporation | $14.00 | 02/22/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 719698721 | CMS |
| Mylan Specialty L.P. | $2,120.00 | 02/20/2020 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 751383241 | CMS |
| Mylan Specialty L.P. | $193.70 | 02/20/2020 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 751383243 | CMS |
| Mylan Specialty L.P. | $117.94 | 02/20/2020 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 751383549 | CMS |
| Mylan Specialty L.P. | $874.50 | 02/20/2020 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 751403001 | CMS |
| Insmed, Inc. | $9.59 | 02/18/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 739692325 | CMS |
| Insmed, Inc. | $93.00 | 02/18/2020 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 739693209 | CMS |
| GlaxoSmithKline, LLC. | $19.08 | 02/17/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 738789543 | CMS |
| Insmed, Inc. | $540.10 | 02/15/2020 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 739691353 | CMS |
| Insmed, Inc. | $770.00 | 02/15/2020 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 739691595 | CMS |
| Insmed, Inc. | $232.96 | 02/14/2020 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 739691523 | CMS |
| Insmed, Inc. | $131.32 | 02/13/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 739691677 | CMS |
| Mylan Specialty L.P. | $2,120.00 | 02/13/2020 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 751404047 | CMS |
| Insmed, Inc. | $12.34 | 02/12/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 739691229 | CMS |
| Insmed, Inc. | $125.00 | 02/12/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 739694479 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $441,079.70 | 291 |
| PY2024 | Principal investigator | $488,241.43 | 318 |
| PY2023 | Principal investigator | $338,591.22 | 78 |
| PY2022 | Principal investigator | $309,620.67 | 112 |
| PY2021 | Principal investigator | $338,390.99 | 210 |
| PY2020 | Principal investigator | $26,804.41 | 9 |
| PY2019 | Principal investigator | $16,541.33 | 8 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
291 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | United Therapeutics Corporation | $1,605.12 | 12/24/2025 | Non-covered Recipient Entity CLINICAL TRIALS CENTER OF MIDDLE TENNESSEE | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | No dispute reported | 06/30/2026 | 1242385067 |
| Principal investigator 1 | United Therapeutics Corporation | $1,605.12 | 12/24/2025 | Non-covered Recipient Entity CLINICAL TRIALS CENTER OF MIDDLE TENNESSEE | An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | No dispute reported | 06/30/2026 | 1242385087 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $34.98 | 12/17/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | A double-blind, randomised, placebo-controlled, parallel group, Phase?IIa trial to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of BI?765423 administered intravenously with or without standard of care in patients with idiopathic pulmonary fibrosis | No dispute reported | 06/30/2026 | 1220716625 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $328.50 | 12/17/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | A double-blind, randomised, placebo-controlled, parallel group, Phase?IIa trial to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of BI?765423 administered intravenously with or without standard of care in patients with idiopathic pulmonary fibrosis | No dispute reported | 06/30/2026 | 1220716627 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $183.21 | 12/17/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | A double-blind, randomised, placebo-controlled, parallel group, Phase?IIa trial to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of BI?765423 administered intravenously with or without standard of care in patients with idiopathic pulmonary fibrosis | No dispute reported | 06/30/2026 | 1220716629 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $69.60 | 12/17/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | A double-blind, randomised, placebo-controlled, parallel group, Phase?IIa trial to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of BI?765423 administered intravenously with or without standard of care in patients with idiopathic pulmonary fibrosis | No dispute reported | 06/30/2026 | 1220716631 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $61.92 | 12/17/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | A double-blind, randomised, placebo-controlled, parallel group, Phase?IIa trial to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of BI?765423 administered intravenously with or without standard of care in patients with idiopathic pulmonary fibrosis | No dispute reported | 06/30/2026 | 1220716633 |
| Principal investigator 1 | United Therapeutics Corporation | $950.00 | 12/17/2025 | Non-covered Recipient Entity CLINICAL TRIALS CENTER OF MIDDLE TENNESSEE | A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) | No dispute reported | 06/30/2026 | 1242385115 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $19,710.70 | 12/15/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) | No dispute reported | 06/30/2026 | 1220806873 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $360.00 | 12/15/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220806965 |
| Principal investigator 1 | Verona Pharma, Inc. | $500.00 | 12/10/2025 | Non-covered Recipient Entity CLINICAL TRIALS CENTER OF MIDD | Verona | No dispute reported | 06/30/2026 | 1232891801 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $3,517.00 | 12/05/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220806793 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $100.00 | 12/05/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220806795 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $300.00 | 12/05/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220806797 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $13,500.00 | 12/05/2025 | Non-covered Recipient Entity CLINICAL TRIALS CENTER OF MIDDLE TENNESSEE LLC | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTIC | No dispute reported | 06/30/2026 | 1192163362 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $640.00 | 12/03/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220806963 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $45.81 | 12/01/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220716493 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3.86 | 12/01/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220716545 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $34.63 | 12/01/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220716547 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $15.00 | 12/01/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | A double-blind, randomised, placebo-controlled, parallel group, Phase?IIa trial to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of BI?765423 administered intravenously with or without standard of care in patients with idiopathic pulmonary fibrosis | No dispute reported | 06/30/2026 | 1220806805 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $34.00 | 12/01/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220806959 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $232.00 | 12/01/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220806961 |
| Principal investigator 1 | United Therapeutics Corporation | $1,436.16 | 11/26/2025 | Non-covered Recipient Entity CLINICAL TRIALS CENTER OF MIDDLE TENNESSEE | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | No dispute reported | 06/30/2026 | 1242385065 |
| Principal investigator 1 | United Therapeutics Corporation | $1,436.16 | 11/26/2025 | Non-covered Recipient Entity CLINICAL TRIALS CENTER OF MIDDLE TENNESSEE | An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | No dispute reported | 06/30/2026 | 1242385085 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $4,935.00 | 11/25/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) | No dispute reported | 06/30/2026 | 1220806871 |
| Principal investigator 1 | United Therapeutics Corporation | $950.00 | 11/19/2025 | Non-covered Recipient Entity CLINICAL TRIALS CENTER OF MIDDLE TENNESSEE | A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) | No dispute reported | 06/30/2026 | 1242385117 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,966.00 | 11/18/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220806801 |
| Principal investigator 1 | United Therapeutics Corporation | $300.00 | 11/14/2025 | Non-covered Recipient Entity CLINICAL TRIALS CENTER OF MIDDLE TENNESSEE | A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) | No dispute reported | 06/30/2026 | 1242385105 |
| Principal investigator 1 | United Therapeutics Corporation | $4,730.88 | 11/12/2025 | Non-covered Recipient Entity CLINICAL TRIALS CENTER OF MIDDLE TENNESSEE | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | No dispute reported | 06/30/2026 | 1242385079 |
| Principal investigator 1 | United Therapeutics Corporation | $4,730.88 | 11/12/2025 | Non-covered Recipient Entity CLINICAL TRIALS CENTER OF MIDDLE TENNESSEE | An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | No dispute reported | 06/30/2026 | 1242385095 |
| Principal investigator 1 | Verona Pharma, Inc. | $13,363.26 | 11/07/2025 | Non-covered Recipient Entity CLINICAL TRIALS CENTER OF MIDD | Verona | No dispute reported | 06/30/2026 | 1232891811 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $50.00 | 11/04/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220806791 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $45.81 | 11/01/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220716491 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3.86 | 11/01/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220716541 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $34.63 | 11/01/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220716543 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $15.00 | 11/01/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | A double-blind, randomised, placebo-controlled, parallel group, Phase?IIa trial to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of BI?765423 administered intravenously with or without standard of care in patients with idiopathic pulmonary fibrosis | No dispute reported | 06/30/2026 | 1220806803 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $34.00 | 11/01/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220806955 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $232.00 | 11/01/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220806957 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $3,247.50 | 10/31/2025 | Non-covered Recipient Entity CLINICAL TRIALS CENTER OF MIDDLE TENNESSEE | A Phase III Multicentre Randomised Double blind Chronic dosing Parallel group Placebo controlled Study to Evaluate the Efficacy and Safety of Two Dose Regimens of Tozorakimab in Participants with Symptomatic Chronic Obstructive Pulmonary Disease COPD with a History of COPD Exacerbations OBERON | No dispute reported | 06/30/2026 | 1185537862 |
| Principal investigator 1 | United Therapeutics Corporation | $700.00 | 10/29/2025 | Non-covered Recipient Entity CLINICAL TRIALS CENTER OF MIDDLE TENNESSEE | A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) | No dispute reported | 06/30/2026 | 1242385113 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,476.00 | 10/28/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220806949 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $73.00 | 10/27/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220716549 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $69.96 | 10/27/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | A double-blind, randomised, placebo-controlled, parallel group, Phase?IIa trial to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of BI?765423 administered intravenously with or without standard of care in patients with idiopathic pulmonary fibrosis | No dispute reported | 06/30/2026 | 1220716605 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $19.98 | 10/27/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | A double-blind, randomised, placebo-controlled, parallel group, Phase?IIa trial to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of BI?765423 administered intravenously with or without standard of care in patients with idiopathic pulmonary fibrosis | No dispute reported | 06/30/2026 | 1220716607 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $474.50 | 10/27/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | A double-blind, randomised, placebo-controlled, parallel group, Phase?IIa trial to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of BI?765423 administered intravenously with or without standard of care in patients with idiopathic pulmonary fibrosis | No dispute reported | 06/30/2026 | 1220716609 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $122.14 | 10/27/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | A double-blind, randomised, placebo-controlled, parallel group, Phase?IIa trial to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of BI?765423 administered intravenously with or without standard of care in patients with idiopathic pulmonary fibrosis | No dispute reported | 06/30/2026 | 1220716611 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $46.40 | 10/27/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | A double-blind, randomised, placebo-controlled, parallel group, Phase?IIa trial to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of BI?765423 administered intravenously with or without standard of care in patients with idiopathic pulmonary fibrosis | No dispute reported | 06/30/2026 | 1220716613 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $40.56 | 10/27/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | A double-blind, randomised, placebo-controlled, parallel group, Phase?IIa trial to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of BI?765423 administered intravenously with or without standard of care in patients with idiopathic pulmonary fibrosis | No dispute reported | 06/30/2026 | 1220716615 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $40.56 | 10/27/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | A double-blind, randomised, placebo-controlled, parallel group, Phase?IIa trial to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of BI?765423 administered intravenously with or without standard of care in patients with idiopathic pulmonary fibrosis | No dispute reported | 06/30/2026 | 1220716617 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $40.56 | 10/27/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | A double-blind, randomised, placebo-controlled, parallel group, Phase?IIa trial to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of BI?765423 administered intravenously with or without standard of care in patients with idiopathic pulmonary fibrosis | No dispute reported | 06/30/2026 | 1220716619 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $40.56 | 10/27/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | A double-blind, randomised, placebo-controlled, parallel group, Phase?IIa trial to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of BI?765423 administered intravenously with or without standard of care in patients with idiopathic pulmonary fibrosis | No dispute reported | 06/30/2026 | 1220716621 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $30.96 | 10/27/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | A double-blind, randomised, placebo-controlled, parallel group, Phase?IIa trial to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of BI?765423 administered intravenously with or without standard of care in patients with idiopathic pulmonary fibrosis | No dispute reported | 06/30/2026 | 1220716623 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $69.00 | 10/27/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220806789 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $500.00 | 10/27/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee | A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety, and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation | No dispute reported | 06/30/2026 | 1226091089 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $322.00 | 10/24/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | A double-blind, randomised, placebo-controlled, parallel group, Phase?IIa trial to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of BI?765423 administered intravenously with or without standard of care in patients with idiopathic pulmonary fibrosis | No dispute reported | 06/30/2026 | 1220716577 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $11.70 | 10/24/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | A double-blind, randomised, placebo-controlled, parallel group, Phase?IIa trial to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of BI?765423 administered intravenously with or without standard of care in patients with idiopathic pulmonary fibrosis | No dispute reported | 06/30/2026 | 1220716579 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $450.00 | 10/24/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | A double-blind, randomised, placebo-controlled, parallel group, Phase?IIa trial to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of BI?765423 administered intravenously with or without standard of care in patients with idiopathic pulmonary fibrosis | No dispute reported | 06/30/2026 | 1220716581 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $75.90 | 10/24/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | A double-blind, randomised, placebo-controlled, parallel group, Phase?IIa trial to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of BI?765423 administered intravenously with or without standard of care in patients with idiopathic pulmonary fibrosis | No dispute reported | 06/30/2026 | 1220716583 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $50.70 | 10/24/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | A double-blind, randomised, placebo-controlled, parallel group, Phase?IIa trial to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of BI?765423 administered intravenously with or without standard of care in patients with idiopathic pulmonary fibrosis | No dispute reported | 06/30/2026 | 1220716585 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $144.00 | 10/24/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | A double-blind, randomised, placebo-controlled, parallel group, Phase?IIa trial to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of BI?765423 administered intravenously with or without standard of care in patients with idiopathic pulmonary fibrosis | No dispute reported | 06/30/2026 | 1220716587 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $203.10 | 10/24/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | A double-blind, randomised, placebo-controlled, parallel group, Phase?IIa trial to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of BI?765423 administered intravenously with or without standard of care in patients with idiopathic pulmonary fibrosis | No dispute reported | 06/30/2026 | 1220716589 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $18.00 | 10/24/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | A double-blind, randomised, placebo-controlled, parallel group, Phase?IIa trial to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of BI?765423 administered intravenously with or without standard of care in patients with idiopathic pulmonary fibrosis | No dispute reported | 06/30/2026 | 1220716591 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $72.30 | 10/24/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | A double-blind, randomised, placebo-controlled, parallel group, Phase?IIa trial to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of BI?765423 administered intravenously with or without standard of care in patients with idiopathic pulmonary fibrosis | No dispute reported | 06/30/2026 | 1220716593 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $105.90 | 10/24/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | A double-blind, randomised, placebo-controlled, parallel group, Phase?IIa trial to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of BI?765423 administered intravenously with or without standard of care in patients with idiopathic pulmonary fibrosis | No dispute reported | 06/30/2026 | 1220716595 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $103.20 | 10/24/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | A double-blind, randomised, placebo-controlled, parallel group, Phase?IIa trial to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of BI?765423 administered intravenously with or without standard of care in patients with idiopathic pulmonary fibrosis | No dispute reported | 06/30/2026 | 1220716597 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $30.60 | 10/24/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | A double-blind, randomised, placebo-controlled, parallel group, Phase?IIa trial to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of BI?765423 administered intravenously with or without standard of care in patients with idiopathic pulmonary fibrosis | No dispute reported | 06/30/2026 | 1220716599 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $8,400.00 | 10/24/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | A double-blind, randomised, placebo-controlled, parallel group, Phase?IIa trial to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of BI?765423 administered intravenously with or without standard of care in patients with idiopathic pulmonary fibrosis | No dispute reported | 06/30/2026 | 1220716601 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $60.55 | 10/24/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | A double-blind, randomised, placebo-controlled, parallel group, Phase?IIa trial to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of BI?765423 administered intravenously with or without standard of care in patients with idiopathic pulmonary fibrosis | No dispute reported | 06/30/2026 | 1220716603 |
| Principal investigator 1 | Verona Pharma, Inc. | $4,950.00 | 10/17/2025 | Non-covered Recipient Entity CLINICAL TRIALS CENTER OF MIDD | Verona | No dispute reported | 06/30/2026 | 1232891799 |
| Principal investigator 1 | United Therapeutics Corporation | $300.00 | 10/08/2025 | Non-covered Recipient Entity CLINICAL TRIALS CENTER OF MIDDLE TENNESSEE | A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) | No dispute reported | 06/30/2026 | 1242385107 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,831.00 | 10/06/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220806787 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $45.81 | 10/01/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220716489 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3.86 | 10/01/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220716537 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $34.63 | 10/01/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220716539 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $150.00 | 10/01/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220806941 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $200.00 | 10/01/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220806943 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $400.00 | 10/01/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220806945 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $3,110.40 | 10/01/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220806947 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $232.00 | 10/01/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220806951 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $34.00 | 10/01/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220806953 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $11.66 | 09/24/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220716535 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $9,723.10 | 09/24/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220806799 |
| Principal investigator 1 | Verona Pharma, Inc. | $15,000.00 | 09/24/2025 | Non-covered Recipient Entity CLINICAL TRIALS CENTER OF MIDD | Verona | No dispute reported | 06/30/2026 | 1232891645 |
| Principal investigator 1 | Verona Pharma, Inc. | $2,000.00 | 09/24/2025 | Non-covered Recipient Entity CLINICAL TRIALS CENTER OF MIDD | Verona | No dispute reported | 06/30/2026 | 1232891647 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $179.80 | 09/23/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) | No dispute reported | 06/30/2026 | 1220806869 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $50.00 | 09/18/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220806785 |
| Principal investigator 1 | United Therapeutics Corporation | $1,000.00 | 09/17/2025 | Non-covered Recipient Entity CLINICAL TRIALS CENTER OF MIDDLE TENNESSEE | A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) | No dispute reported | 06/30/2026 | 1242385119 |
| Principal investigator 1 | Verona Pharma, Inc. | $2,500.00 | 09/17/2025 | Non-covered Recipient Entity CLINICAL TRIALS CENTER OF MIDD | Verona | No dispute reported | 06/30/2026 | 1232891649 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,900.00 | 09/04/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220806831 |
| Principal investigator 1 | United Therapeutics Corporation | $300.00 | 09/03/2025 | Non-covered Recipient Entity CLINICAL TRIALS CENTER OF MIDDLE TENNESSEE | A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) | No dispute reported | 06/30/2026 | 1242385103 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $45.81 | 09/01/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220716473 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $34.63 | 09/01/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220716527 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3.86 | 09/01/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220716529 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $232.00 | 09/01/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220806937 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $34.00 | 09/01/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220806939 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $450.00 | 08/28/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220806931 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $360.00 | 08/28/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220806933 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,083.35 | 08/28/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220806935 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $79.92 | 08/26/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220716477 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $36.50 | 08/26/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220716479 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $61.07 | 08/26/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220716481 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $20.73 | 08/26/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220716483 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1.68 | 08/26/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220716485 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $7.50 | 08/26/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220716487 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $151.58 | 08/26/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220716531 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $182.50 | 08/26/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220716533 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $320.00 | 08/21/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) | No dispute reported | 06/30/2026 | 1220806867 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $3,411.90 | 08/21/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220806929 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,416.96 | 08/18/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220806927 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $250.00 | 08/15/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220806781 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $300.00 | 08/15/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220806783 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $3,738.00 | 08/14/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220806779 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,900.00 | 08/14/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) | No dispute reported | 06/30/2026 | 1220806865 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $45.81 | 08/01/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220716471 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3.86 | 08/01/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220716523 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $34.63 | 08/01/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220716525 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $800.00 | 08/01/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) | No dispute reported | 06/30/2026 | 1220806853 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $480.00 | 08/01/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) | No dispute reported | 06/30/2026 | 1220806855 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $225.00 | 08/01/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) | No dispute reported | 06/30/2026 | 1220806857 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $520.00 | 08/01/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) | No dispute reported | 06/30/2026 | 1220806859 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $800.00 | 08/01/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) | No dispute reported | 06/30/2026 | 1220806861 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $100.00 | 08/01/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) | No dispute reported | 06/30/2026 | 1220806863 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $232.00 | 08/01/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220806923 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $34.00 | 08/01/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220806925 |
| Principal investigator 1 | United Therapeutics Corporation | $4,276.80 | 08/01/2025 | Non-covered Recipient Entity CLINICAL TRIALS CENTER OF MIDDLE TENNESSEE | A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) | No dispute reported | 06/30/2026 | 1242385125 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $450.00 | 07/30/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220806913 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $277.50 | 07/30/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220806915 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,600.00 | 07/30/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220806917 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $280.00 | 07/30/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220806919 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $480.00 | 07/30/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220806921 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $73.00 | 07/28/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220716475 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $760.00 | 07/15/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220806907 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $200.00 | 07/14/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220806773 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $500.00 | 07/14/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220806775 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $300.00 | 07/14/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220806777 |
| Principal investigator 1 | CSL Behring | $1,250.00 | 07/11/2025 | Non-covered Recipient Entity Clinical Trials Center of Middle Tennessee, LLC | A Randomized, Double-blind, Placebo-controlled, Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of CSL312 in Subjects With Idiopathic Pulmonary Fibrosis | No dispute reported | 06/30/2026 | 1252665927 |
| Principal investigator 1 | United Therapeutics Corporation | $300.00 | 07/11/2025 | Non-covered Recipient Entity CLINICAL TRIALS CENTER OF MIDDLE TENNESSEE | A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) | No dispute reported | 06/30/2026 | 1242385101 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,630.00 | 07/10/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220806771 |
| Principal investigator 1 | United Therapeutics Corporation | $3,041.28 | 07/08/2025 | Non-covered Recipient Entity CLINICAL TRIALS CENTER OF MIDDLE TENNESSEE | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | No dispute reported | 06/30/2026 | 1242385077 |
| Principal investigator 1 | United Therapeutics Corporation | $3,041.28 | 07/08/2025 | Non-covered Recipient Entity CLINICAL TRIALS CENTER OF MIDDLE TENNESSEE | An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | No dispute reported | 06/30/2026 | 1242385093 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $45.81 | 07/01/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220716469 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $34.63 | 07/01/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220716519 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3.86 | 07/01/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220716521 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $34.00 | 07/01/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220806909 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $232.00 | 07/01/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220806911 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $4,382.52 | 06/25/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220806829 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $100.00 | 06/24/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) | No dispute reported | 06/30/2026 | 1220806849 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $40.00 | 06/24/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) | No dispute reported | 06/30/2026 | 1220806851 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,476.00 | 06/24/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220806905 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $640.00 | 06/20/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220806903 |
| Principal investigator 1 | United Therapeutics Corporation | $300.00 | 06/18/2025 | Non-covered Recipient Entity CLINICAL TRIALS CENTER OF MIDDLE TENNESSEE | A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) | No dispute reported | 06/30/2026 | 1242385099 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $800.00 | 06/16/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) | No dispute reported | 06/30/2026 | 1220806843 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $800.00 | 06/16/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) | No dispute reported | 06/30/2026 | 1220806845 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $840.00 | 06/16/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) | No dispute reported | 06/30/2026 | 1220806847 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $3,052.00 | 06/11/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220806769 |
| Principal investigator 1 | United Therapeutics Corporation | $2,534.40 | 06/11/2025 | Non-covered Recipient Entity CLINICAL TRIALS CENTER OF MIDDLE TENNESSEE | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | No dispute reported | 06/30/2026 | 1242385075 |
| Principal investigator 1 | United Therapeutics Corporation | $2,534.40 | 06/11/2025 | Non-covered Recipient Entity CLINICAL TRIALS CENTER OF MIDDLE TENNESSEE | An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | No dispute reported | 06/30/2026 | 1242385091 |
| Principal investigator 1 | United Therapeutics Corporation | $600.00 | 06/11/2025 | Non-covered Recipient Entity CLINICAL TRIALS CENTER OF MIDDLE TENNESSEE | A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) | No dispute reported | 06/30/2026 | 1242385111 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $50.00 | 06/10/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220806767 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $100.00 | 06/06/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220806765 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $920.00 | 06/06/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220806901 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $45.81 | 06/01/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220716447 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $34.63 | 06/01/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220716513 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3.86 | 06/01/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220716515 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $4,562.00 | 06/01/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220806763 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $232.00 | 06/01/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220806897 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $34.00 | 06/01/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220806899 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $50.00 | 05/28/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220806761 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $19.98 | 05/27/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220716451 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $36.50 | 05/27/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220716453 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1.68 | 05/27/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220716455 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $5.00 | 05/27/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220716457 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $73.00 | 05/27/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220716517 |
| Principal investigator 1 | United Therapeutics Corporation | $1,890.00 | 05/21/2025 | Non-covered Recipient Entity CLINICAL TRIALS CENTER OF MIDDLE TENNESSEE | A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) | No dispute reported | 06/30/2026 | 1242385121 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,240.00 | 05/15/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220806825 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $11,683.00 | 05/13/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220806759 |
| Principal investigator 1 | Genentech, Inc. | $4,928.00 | 05/13/2025 | Non-covered Recipient Entity CLINICAL TRIALS CENTER OF MIDD | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | No dispute reported | 06/30/2026 | 1211588552 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $10,863.90 | 05/09/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220806889 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $640.00 | 05/07/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) | No dispute reported | 06/30/2026 | 1220806839 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $8,008.20 | 05/07/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) | No dispute reported | 06/30/2026 | 1220806841 |
| Principal investigator 1 | United Therapeutics Corporation | $1,436.16 | 05/07/2025 | Non-covered Recipient Entity CLINICAL TRIALS CENTER OF MIDDLE TENNESSEE | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | No dispute reported | 06/30/2026 | 1242385063 |
| Principal investigator 1 | United Therapeutics Corporation | $1,960.20 | 05/07/2025 | Non-covered Recipient Entity CLINICAL TRIALS CENTER OF MIDDLE TENNESSEE | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | No dispute reported | 06/30/2026 | 1242385071 |
| Principal investigator 1 | United Therapeutics Corporation | $1,960.20 | 05/07/2025 | Non-covered Recipient Entity CLINICAL TRIALS CENTER OF MIDDLE TENNESSEE | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | No dispute reported | 06/30/2026 | 1242385073 |
| Principal investigator 1 | Genentech, Inc. | $3,777.00 | 05/06/2025 | Non-covered Recipient Entity CLINICAL TRIALS CENTER OF MIDD | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | No dispute reported | 06/30/2026 | 1211588526 |
| Principal investigator 1 | Genentech, Inc. | $2,500.00 | 05/06/2025 | Non-covered Recipient Entity CLINICAL TRIALS CENTER OF MIDD | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | No dispute reported | 06/30/2026 | 1211588541 |
| Principal investigator 1 | Genentech, Inc. | $2,464.00 | 05/06/2025 | Non-covered Recipient Entity CLINICAL TRIALS CENTER OF MIDD | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | No dispute reported | 06/30/2026 | 1211588545 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $28.00 | 05/02/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220806895 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $45.81 | 05/01/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220716445 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $34.63 | 05/01/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220716509 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3.86 | 05/01/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220716511 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $34.00 | 05/01/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220806891 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $232.00 | 05/01/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220806893 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $800.00 | 04/30/2025 | Non-covered Recipient Entity DIABETES AND ENDOCRINOLOGY ASSOCIATES OF STARK COUNTY, INC | A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Extension Study to Evaluate the Long-term Efficacy and Safety of Tozorakimab (MEDI3506) in Participants with Chronic Obstructive Pulmonary Disease (COPD) with a History of Exacerbations | No dispute reported | 06/30/2026 | 1185537854 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $1,153.68 | 04/23/2025 | Non-covered Recipient Entity DIABETES AND ENDOCRINOLOGY ASSOCIATES OF STARK COUNTY, INC | A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium and Formoterol Fumarate MeterednDose Inhaler Relative to Glycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease THARROS | No dispute reported | 06/30/2026 | 1185537864 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $48.50 | 04/23/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220716449 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.96 | 04/23/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220716459 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $73.00 | 04/23/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220716461 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $427.49 | 04/23/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220716463 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $103.65 | 04/23/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220716465 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $11.76 | 04/23/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220716467 |
| Principal investigator 1 | United Therapeutics Corporation | $1,436.16 | 04/23/2025 | Non-covered Recipient Entity CLINICAL TRIALS CENTER OF MIDDLE TENNESSEE | An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | No dispute reported | 06/30/2026 | 1242385083 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $45,603.68 | 04/22/2025 | Non-covered Recipient Entity CLINICAL TRIALS CENTER OF MIDDLE TENNESSEE | Randomized Double blind Placebo controlled Parallel Group Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adult Participants with Moderate to Very Severe Chronic Obstructive Pulmonary Disease COPD | No dispute reported | 06/30/2026 | 1185537856 |
| Principal investigator 1 | Genentech, Inc. | $2,464.00 | 04/22/2025 | Non-covered Recipient Entity CLINICAL TRIALS CENTER OF MIDD | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | No dispute reported | 06/30/2026 | 1211588522 |
| Principal investigator 1 | Genentech, Inc. | $2,464.00 | 04/22/2025 | Non-covered Recipient Entity CLINICAL TRIALS CENTER OF MIDD | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | No dispute reported | 06/30/2026 | 1211588530 |
| Principal investigator 1 | Genentech, Inc. | $130.00 | 04/22/2025 | Non-covered Recipient Entity CLINICAL TRIALS CENTER OF MIDD | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | No dispute reported | 06/30/2026 | 1211588533 |
| Principal investigator 1 | Genentech, Inc. | $6,648.00 | 04/15/2025 | Non-covered Recipient Entity CLINICAL TRIALS CENTER OF MIDD | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | No dispute reported | 06/30/2026 | 1211588537 |
| Principal investigator 1 | Genentech, Inc. | $1,200.00 | 04/10/2025 | Non-covered Recipient Entity CLINICAL TRIALS CENTER OF MIDD | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | No dispute reported | 06/30/2026 | 1211588549 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $2,459.01 | 04/09/2025 | Non-covered Recipient Entity DIABETES AND ENDOCRINOLOGY ASSOCIATES OF STARK COUNTY, INC | A Multicenter, Randomized, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Benralizumab 100 mg in Patients with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) with a History of Frequent COPD Exacerbations and Elevated Peripheral Blood Eosinophils (RESOLUTE) | No dispute reported | 06/30/2026 | 1185537848 |
| Principal investigator 1 | United Therapeutics Corporation | $844.80 | 04/09/2025 | Non-covered Recipient Entity CLINICAL TRIALS CENTER OF MIDDLE TENNESSEE | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | No dispute reported | 06/30/2026 | 1242385061 |
| Principal investigator 1 | United Therapeutics Corporation | $844.80 | 04/09/2025 | Non-covered Recipient Entity CLINICAL TRIALS CENTER OF MIDDLE TENNESSEE | An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | No dispute reported | 06/30/2026 | 1242385081 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $520.00 | 04/08/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220806879 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,640.00 | 04/08/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220806881 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $400.00 | 04/08/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220806883 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $45.81 | 04/01/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220716443 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $22.00 | 04/01/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220806827 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $34.00 | 04/01/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220806885 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $232.00 | 04/01/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220806887 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $2,574.14 | 03/27/2025 | Non-covered Recipient Entity CLINICAL TRIALS CENTER OF MIDDLE TENNESSEE | A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler | No dispute reported | 06/30/2026 | 1185537852 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $159.84 | 03/25/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220716429 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $109.50 | 03/25/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220716431 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $122.14 | 03/25/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220716433 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $41.46 | 03/25/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220716435 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3.36 | 03/25/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220716437 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $15.00 | 03/25/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220716439 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $23.32 | 03/25/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220716505 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $109.50 | 03/25/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220716507 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $5,046.30 | 03/25/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220806877 |
| Principal investigator 1 | United Therapeutics Corporation | $300.00 | 03/19/2025 | Non-covered Recipient Entity CLINICAL TRIALS CENTER OF MIDDLE TENNESSEE | A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) | No dispute reported | 06/30/2026 | 1242385097 |
| Principal investigator 1 | United Therapeutics Corporation | $350.00 | 03/19/2025 | Non-covered Recipient Entity CLINICAL TRIALS CENTER OF MIDDLE TENNESSEE | A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) | No dispute reported | 06/30/2026 | 1242385109 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $3,713.40 | 03/18/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220806875 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,910.70 | 03/11/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) | No dispute reported | 06/30/2026 | 1220806835 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $250.00 | 03/11/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) | No dispute reported | 06/30/2026 | 1220806837 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $45.81 | 03/01/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220716423 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $103.87 | 03/01/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | PDE4 Phase III trial in IPF patients | No dispute reported | 06/30/2026 | 1220716659 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $11.57 | 03/01/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | PDE4 Phase III trial in IPF patients | No dispute reported | 06/30/2026 | 1220716661 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $22.00 | 03/01/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220806819 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $232.00 | 03/01/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220806821 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $34.00 | 03/01/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220806823 |
| Principal investigator 1 | United Therapeutics Corporation | $1,689.60 | 02/26/2025 | Non-covered Recipient Entity CLINICAL TRIALS CENTER OF MIDDLE TENNESSEE | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | No dispute reported | 06/30/2026 | 1242385069 |
| Principal investigator 1 | United Therapeutics Corporation | $1,689.60 | 02/26/2025 | Non-covered Recipient Entity CLINICAL TRIALS CENTER OF MIDDLE TENNESSEE | An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | No dispute reported | 06/30/2026 | 1242385089 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $81.62 | 02/25/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220716497 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $255.50 | 02/25/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220716499 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $6.72 | 02/25/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220716501 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $6.00 | 02/25/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220716503 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $109.50 | 02/25/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | PDE4 Phase III trial in PF-ILD | No dispute reported | 06/30/2026 | 1220716559 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $42.06 | 02/25/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | PDE4 Phase III trial in PF-ILD | No dispute reported | 06/30/2026 | 1220716561 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $13.32 | 02/25/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | PDE4 Phase III trial in PF-ILD | No dispute reported | 06/30/2026 | 1220716563 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $13.32 | 02/25/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | PDE4 Phase III trial in PF-ILD | No dispute reported | 06/30/2026 | 1220716565 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $13.32 | 02/25/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | PDE4 Phase III trial in PF-ILD | No dispute reported | 06/30/2026 | 1220716567 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $13.32 | 02/25/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | PDE4 Phase III trial in PF-ILD | No dispute reported | 06/30/2026 | 1220716569 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4.80 | 02/25/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | PDE4 Phase III trial in PF-ILD | No dispute reported | 06/30/2026 | 1220716571 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $6,963.26 | 02/21/2025 | Non-covered Recipient Entity CLINICAL TRIALS CENTER OF MIDDLE TENNESSEE | A Multicenter, Randomized, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Benralizumab 100 mg in Patients with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) with a History of Frequent COPD Exacerbations and Elevated Peripheral Blood Eosinophils (RESOLUTE) | No dispute reported | 06/30/2026 | 1185537850 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $4,425.90 | 02/12/2025 | Non-covered Recipient Entity CLINICAL TRIALS CENTER OF MIDDLE TENNESSEE | A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Extension Study to Evaluate the Long-term Efficacy and Safety of Tozorakimab (MEDI3506) in Participants with Chronic Obstructive Pulmonary Disease (COPD) with a History of Exacerbations | No dispute reported | 06/30/2026 | 1185537858 |
| Principal investigator 1 | United Therapeutics Corporation | $2,500.00 | 02/12/2025 | Non-covered Recipient Entity CLINICAL TRIALS CENTER OF MIDDLE TENNESSEE | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | No dispute reported | 06/30/2026 | 1242385055 |
| Principal investigator 1 | United Therapeutics Corporation | $2,787.84 | 02/12/2025 | Non-covered Recipient Entity CLINICAL TRIALS CENTER OF MIDDLE TENNESSEE | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | No dispute reported | 06/30/2026 | 1242385057 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $4,871.00 | 02/10/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220806757 |
| Principal investigator 1 | Genentech, Inc. | $7,057.00 | 02/06/2025 | Non-covered Recipient Entity CLINICAL TRIALS CENTER OF MIDDLE TENNESSEE LLC | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | No dispute reported | 06/30/2026 | 1211588557 |
| Principal investigator 1 | United Therapeutics Corporation | $10,400.00 | 02/05/2025 | Non-covered Recipient Entity CLINICAL TRIALS CENTER OF MIDDLE TENNESSEE | A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) | No dispute reported | 06/30/2026 | 1242385127 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $45.81 | 02/01/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220716421 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 02/01/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | PDE4 Phase III trial in PF-ILD | No dispute reported | 06/30/2026 | 1220716553 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $14.16 | 02/01/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | PDE4 Phase III trial in PF-ILD | No dispute reported | 06/30/2026 | 1220716555 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $14.16 | 02/01/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | PDE4 Phase III trial in PF-ILD | No dispute reported | 06/30/2026 | 1220716557 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 02/01/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | PDE4 Phase III trial in IPF patients | No dispute reported | 06/30/2026 | 1220716639 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 02/01/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | PDE4 Phase III trial in IPF patients | No dispute reported | 06/30/2026 | 1220716641 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $14.16 | 02/01/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | PDE4 Phase III trial in IPF patients | No dispute reported | 06/30/2026 | 1220716643 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $14.16 | 02/01/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | PDE4 Phase III trial in IPF patients | No dispute reported | 06/30/2026 | 1220716645 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $103.87 | 02/01/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | PDE4 Phase III trial in IPF patients | No dispute reported | 06/30/2026 | 1220716647 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $11.57 | 02/01/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | PDE4 Phase III trial in IPF patients | No dispute reported | 06/30/2026 | 1220716649 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $232.00 | 02/01/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220806813 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $34.00 | 02/01/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220806815 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $22.00 | 02/01/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220806817 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $36,583.37 | 01/29/2025 | Non-covered Recipient Entity CLINICAL TRIALS CENTER OF MIDDLE TENNESSEE | A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium and Formoterol Fumarate MeterednDose Inhaler Relative to Glycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease THARROS | No dispute reported | 06/30/2026 | 1185537860 |
| Principal investigator 1 | United Therapeutics Corporation | $2,787.84 | 01/29/2025 | Non-covered Recipient Entity CLINICAL TRIALS CENTER OF MIDDLE TENNESSEE | An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | No dispute reported | 06/30/2026 | 1242385059 |
| Principal investigator 1 | United Therapeutics Corporation | $2,650.05 | 01/29/2025 | Non-covered Recipient Entity CLINICAL TRIALS CENTER OF MIDDLE TENNESSEE | A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) | No dispute reported | 06/30/2026 | 1242385123 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.96 | 01/27/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220716425 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $109.50 | 01/27/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220716427 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $46.64 | 01/27/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) | No dispute reported | 06/30/2026 | 1220716495 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $9,553.50 | 01/21/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) | No dispute reported | 06/30/2026 | 1220806833 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $45.81 | 01/01/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220716441 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 01/01/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | PDE4 Phase III trial in PF-ILD | No dispute reported | 06/30/2026 | 1220716551 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $14.16 | 01/01/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | PDE4 Phase III trial in PF-ILD | No dispute reported | 06/30/2026 | 1220716573 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $14.16 | 01/01/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | PDE4 Phase III trial in PF-ILD | No dispute reported | 06/30/2026 | 1220716575 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 01/01/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | PDE4 Phase III trial in IPF patients | No dispute reported | 06/30/2026 | 1220716635 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 01/01/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | PDE4 Phase III trial in IPF patients | No dispute reported | 06/30/2026 | 1220716637 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $14.16 | 01/01/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | PDE4 Phase III trial in IPF patients | No dispute reported | 06/30/2026 | 1220716651 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $14.16 | 01/01/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | PDE4 Phase III trial in IPF patients | No dispute reported | 06/30/2026 | 1220716653 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $103.87 | 01/01/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | PDE4 Phase III trial in IPF patients | No dispute reported | 06/30/2026 | 1220716655 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $11.57 | 01/01/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | PDE4 Phase III trial in IPF patients | No dispute reported | 06/30/2026 | 1220716657 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $22.00 | 01/01/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220806807 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $232.00 | 01/01/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220806809 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $34.00 | 01/01/2025 | Non-covered Recipient Entity Clinical Trials Center Of Middle Tennessee LLC | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) | No dispute reported | 06/30/2026 | 1220806811 |